CLINICAL TRIALS PROFILE FOR HYDROCORTISONE SODIUM PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for HYDROCORTISONE SODIUM PHOSPHATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00185692 ↗ | Allogeneic Transplantation From Related Haploidentical Donors | Completed | Stanford University | Phase 2 | 2000-08-01 | The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG). |
| NCT01186328 ↗ | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | Terminated | Enzon Pharmaceuticals, Inc. | Phase 1 | 2010-08-24 | An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction. |
| NCT01186328 ↗ | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | 2010-08-24 | An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROCORTISONE SODIUM PHOSPHATE
Condition Name
Clinical Trial Locations for HYDROCORTISONE SODIUM PHOSPHATE
Trials by Country
Clinical Trial Progress for HYDROCORTISONE SODIUM PHOSPHATE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROCORTISONE SODIUM PHOSPHATE
Sponsor Name
